<DOC>
	<DOCNO>NCT00830414</DOCNO>
	<brief_summary>This study compare rate extents medroxyprogesterone absorption two medroxyprogesterone acetate injection formulation follow single 150 mg intramuscular ( IM ) injection healthy postmenopausal woman .</brief_summary>
	<brief_title>Medroxyprogesterone Acetate Injection 150 mg/1 mL Postmenopausal Women</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method</detailed_description>
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<criteria>Inclusion Criteria Screening Demographics : All volunteer select study healthy postmenopausal woman 45 year age old time dose . The weight range exceed ±20 % height body frame per Desirable Weights Women 1983 Metropolitan Height Weight Table . Screening Procedures : Each volunteer complete screening process within 28 day prior period I dose . Consent document screen evaluation HIV antibody determination review , discuss sign potential participant full implementation screening procedure . Screening include general observation , physical examination , demographic , medical medication history , electrocardiogram , sit blood pressure pulse , respiratory rate temperature . The physical examination include , may limit , evaluation cardiovascular , gastrointestinal , respiratory central nervous system . Screening include Gynecological examination ( PAP smear , breast ) show clinically relevant finding , e.g . cytological smear classify accord Papanicolau ( PAP ) high grade II . The screen clinical laboratory procedure include : HEMATOLOGY : hematocrit , hemoglobin , WBC count differential , RBC count , platelet count CLINICAL CHEMISTRY : serum creatinine , BUN , glucose , AST ( GOT ) , ALT ( GPT ) , albumin , total bilirubin , total protein , alkaline phosphatase HIV antibody , hepatitis GB surface antigen , anti hepatitis C virus screen URINALYSIS : dipstick ; full microscopic examination dipstick positive URINE DRUG SCREEN : amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine metabolite , opiates Ethyl alcohol measure use breath test ( alcomat ) FSH ( verify postmenopausal status ) 17βEstradiol ( verify postmenopausal status ) SERUM PREGNANCY SCREEN Is female : Is postmenopausal least 1 year serum FSH level great equal 30 mIU/mL serum 17βestradiol level less 30 pg/mL . Exclusion Criteria Volunteers recent history drug alcohol addiction abuse . Volunteers presence clinically significant disorder involve cardiovascular , respiratory , renal , gastrointestinal , immunologic , hematologic , endocrine , gynecologic neurologic system ( ) psychiatric disease ( determined clinical investigator coinvestigators ) . Volunteers whose clinical laboratory test value show clinically relevant deviation normal confirmed reexamination . Volunteers demonstrate positive hepatitis B surface antigen screen , positive anti HCV screen reactive HIV antibody screen . Volunteers demonstrate positive drug abuse screen screen study . Volunteers demonstrate positive pregnancy screen . Volunteers history allergic response ( ) medroxyprogesterone acetate relate drug . Volunteers history clinically significant allergy include drug allergy . Volunteers history undiagnosed vaginal bleeding . Volunteers personal immediate family ( mother , sister , daughter ) history breast cancer . Volunteers history thromboembolic disorder , thrombophlebitis , history anticoagulant use aspirin . Volunteers clinically significant illness 4 week prior Period I dose ( determined clinical investigator coinvestigators ) . Volunteers currently use tobacco product . Volunteers take drug know induce inhibit hepatic drug metabolism 30 day prior Period I dose . Volunteers report donate great 450 mL blood within 30 day prior dose . All subject advise donate blood four week complete study . Volunteers donate plasma ( e.g . plasmapheresis ) within 14 day prior dose . All subject advise donate plasma four week complete study . Volunteers report receive investigational drug within 30 day prior dose . Volunteers report take systemic prescription medication 14 day prior dose ( hormone replacement therapy ( HRT ) 4 week prior dose ) .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>